GB Sciences, Inc. (GBLX)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.42 Million USD | -15.06% |
| 2022 | 1.67 Million USD | -10.51% |
| 2021 | 1.86 Million USD | -6.64% |
| 2020 | 2 Million USD | -69.13% |
| 2019 | 6.48 Million USD | -58.97% |
| 2018 | 15.8 Million USD | -19.18% |
| 2017 | 19.55 Million USD | 118.87% |
| 2016 | 8.93 Million USD | 28.37% |
| 2015 | 6.95 Million USD | -12.73% |
| 2014 | 7.97 Million USD | 4146.83% |
| 2013 | 187.76 Thousand USD | 147.97% |
| 2012 | 75.71 Thousand USD | -26.37% |
| 2011 | 102.84 Thousand USD | -59.07% |
| 2010 | 251.23 Thousand USD | -90.47% |
| 2009 | 2.63 Million USD | 2159.91% |
| 2008 | 116.62 Thousand USD | -22.52% |
| 2007 | 150.51 Thousand USD | -90.8% |
| 2006 | 1.63 Million USD | 328.25% |
| 2005 | 381.95 Thousand USD | 13.09% |
| 2004 | 337.74 Thousand USD | 369.26% |
| 2003 | 71.97 Thousand USD | -18.39% |
| 2002 | 88.19 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 Q1 | 265.12 Thousand USD | -49.94% |
| 2023 Q3 | 234 Thousand USD | -57.57% |
| 2023 Q4 | 369.88 Thousand USD | 58.07% |
| 2023 FY | 1.41 Million USD | -15.09% |
| 2023 Q2 | 551.49 Thousand USD | 108.01% |
| 2022 Q3 | 407.3 Thousand USD | 47.66% |
| 2022 Q4 | 529.62 Thousand USD | 30.03% |
| 2022 FY | 1.67 Million USD | -10.51% |
| 2022 Q1 | 459.51 Thousand USD | 1.89% |
| 2022 Q2 | 275.83 Thousand USD | -39.97% |
| 2021 Q2 | 411.54 Thousand USD | -16.59% |
| 2021 Q3 | 512.78 Thousand USD | 24.6% |
| 2021 Q4 | 450.99 Thousand USD | -12.05% |
| 2021 FY | 1.86 Million USD | -6.64% |
| 2021 Q1 | 493.4 Thousand USD | 52.22% |
| 2020 FY | 2 Million USD | -69.13% |
| 2020 Q1 | 804.7 Thousand USD | -36.63% |
| 2020 Q4 | 324.13 Thousand USD | -51.64% |
| 2020 Q2 | 491.81 Thousand USD | -38.88% |
| 2020 Q3 | 670.31 Thousand USD | 36.29% |
| 2019 Q2 | 1.4 Million USD | -38.11% |
| 2019 FY | 6.48 Million USD | -58.97% |
| 2019 Q1 | 2.26 Million USD | -40.13% |
| 2019 Q3 | 1.74 Million USD | 24.33% |
| 2019 Q4 | 1.26 Million USD | -27.21% |
| 2018 Q4 | 3.78 Million USD | 26.98% |
| 2018 Q1 | 4.46 Million USD | -34.12% |
| 2018 Q3 | 2.98 Million USD | -34.72% |
| 2018 Q2 | 4.56 Million USD | 2.36% |
| 2018 FY | 15.8 Million USD | -19.18% |
| 2017 Q3 | 7.1 Million USD | 155.69% |
| 2017 Q1 | 2.87 Million USD | 25.24% |
| 2017 FY | 19.55 Million USD | 118.87% |
| 2017 Q4 | 6.77 Million USD | -4.66% |
| 2017 Q2 | 2.77 Million USD | -3.32% |
| 2016 FY | 8.93 Million USD | 28.37% |
| 2016 Q4 | 2.29 Million USD | -28.61% |
| 2016 Q2 | 2.19 Million USD | 81.95% |
| 2016 Q1 | 1.2 Million USD | -25.17% |
| 2016 Q3 | 3.21 Million USD | 46.3% |
| 2015 Q2 | 2.69 Million USD | 76.86% |
| 2015 FY | 6.95 Million USD | -12.73% |
| 2015 Q1 | 1.52 Million USD | -62.13% |
| 2015 Q4 | 1.61 Million USD | 42.98% |
| 2015 Q3 | 1.12 Million USD | -58.08% |
| 2014 Q1 | 1.49 Million USD | 1037.13% |
| 2014 Q4 | 4.02 Million USD | 493.26% |
| 2014 FY | 7.97 Million USD | 4146.83% |
| 2014 Q3 | 677.73 Thousand USD | -61.93% |
| 2014 Q2 | 1.78 Million USD | 19.06% |
| 2013 Q3 | 12.8 Thousand USD | -8.45% |
| 2013 Q2 | 13.98 Thousand USD | -52.58% |
| 2013 Q1 | 29.48 Thousand USD | 44.51% |
| 2013 FY | 187.76 Thousand USD | 147.97% |
| 2013 Q4 | 131.48 Thousand USD | 927.18% |
| 2012 Q1 | 31.68 Thousand USD | 417.8% |
| 2012 Q4 | 20.4 Thousand USD | 270.39% |
| 2012 FY | 75.71 Thousand USD | -26.37% |
| 2012 Q2 | 18.12 Thousand USD | -42.81% |
| 2012 Q3 | 5509.00 USD | -69.6% |
| 2011 Q2 | 21.93 Thousand USD | -61.37% |
| 2011 Q3 | 18.02 Thousand USD | -17.81% |
| 2011 Q4 | 6119.00 USD | -66.05% |
| 2011 FY | 102.84 Thousand USD | -59.07% |
| 2011 Q1 | 56.76 Thousand USD | 151.83% |
| 2010 Q4 | -109.52 Thousand USD | -237.39% |
| 2010 Q1 | 221.17 Thousand USD | -24.44% |
| 2010 FY | 251.23 Thousand USD | -90.47% |
| 2010 Q3 | 79.71 Thousand USD | 33.16% |
| 2010 Q2 | 59.86 Thousand USD | -72.93% |
| 2009 Q2 | 1.91 Million USD | 8423.48% |
| 2009 Q3 | 404.33 Thousand USD | -78.9% |
| 2009 Q4 | 292.7 Thousand USD | -27.61% |
| 2009 FY | 2.63 Million USD | 2159.91% |
| 2009 Q1 | 22.47 Thousand USD | -30.97% |
| 2008 Q2 | 19.14 Thousand USD | -61.09% |
| 2008 Q3 | 15.71 Thousand USD | -17.92% |
| 2008 FY | 116.62 Thousand USD | -22.52% |
| 2008 Q4 | 32.56 Thousand USD | 107.23% |
| 2008 Q1 | 49.2 Thousand USD | 105.2% |
| 2007 Q3 | 355.47 Thousand USD | -12.95% |
| 2007 Q4 | -945.91 Thousand USD | -366.1% |
| 2007 Q2 | 408.36 Thousand USD | 22.78% |
| 2007 Q1 | 332.59 Thousand USD | -27.32% |
| 2007 FY | 150.51 Thousand USD | -90.8% |
| 2006 Q4 | 457.63 Thousand USD | -8.2% |
| 2006 Q2 | 473.74 Thousand USD | 91.7% |
| 2006 FY | 1.63 Million USD | 328.25% |
| 2006 Q1 | 247.12 Thousand USD | 48.89% |
| 2006 Q3 | 498.52 Thousand USD | 5.23% |
| 2005 Q1 | 83.89 Thousand USD | -1.1% |
| 2005 FY | 381.95 Thousand USD | 13.09% |
| 2005 Q3 | 52.42 Thousand USD | -34.19% |
| 2005 Q2 | 79.66 Thousand USD | -5.04% |
| 2005 Q4 | 165.97 Thousand USD | 216.58% |
| 2004 Q4 | 84.82 Thousand USD | -51.38% |
| 2004 Q3 | 174.45 Thousand USD | 122.33% |
| 2004 Q1 | 13.59 Thousand USD | -38.93% |
| 2004 Q2 | 78.46 Thousand USD | 477.2% |
| 2004 FY | 337.74 Thousand USD | 369.26% |
| 2003 Q3 | 13.86 Thousand USD | -5.88% |
| 2003 FY | 71.97 Thousand USD | -18.39% |
| 2003 Q4 | 22.25 Thousand USD | 60.51% |
| 2003 Q1 | 21.11 Thousand USD | 28.34% |
| 2003 Q2 | 14.73 Thousand USD | -30.22% |
| 2002 Q3 | 29.51 Thousand USD | 97.52% |
| 2002 FY | 88.19 Thousand USD | 0.0% |
| 2002 Q4 | 16.45 Thousand USD | -44.25% |
| 2002 Q1 | 27.29 Thousand USD | 0.0% |
| 2002 Q2 | 14.94 Thousand USD | -45.25% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | -6.371% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 71.827% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 95.193% |
| Nascent Biotech, Inc. | 2.22 Million USD | 36.297% |
| Rebus Holdings, Inc. | 664 Thousand USD | -113.932% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 96.187% |
| Qrons Inc. | 643.67 Thousand USD | -120.687% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -264.639% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 97.527% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -241.897% |
| Skye Bioscience, Inc. | 13.54 Million USD | 89.515% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 98.363% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 71.116% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -442.747% |
| SQZ Biotechnologies Company | 85.61 Million USD | 98.341% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | 51.29% |
| Propanc Biopharma, Inc. | 1.5 Million USD | 5.419% |
| Mesoblast Limited | 5.9 Million USD | 75.932% |
| Marizyme, Inc. | 19.23 Million USD | 92.617% |
| Genus plc | 147.7 Million USD | 99.038% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 83.82% |
| Pharming Group N.V. | 225.49 Million USD | 99.37% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | 30.663% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -5.886% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 82.965% |
| ContraFect Corporation | 56.88 Million USD | 97.503% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 67.779% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | 3.939% |
| IMV Inc. | 37.7 Million USD | 96.233% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | 49.092% |
| MultiCell Technologies, Inc. | 567.42 USD | -250245.247% |
| ONE Bio Corp. | 6.44 Million USD | 77.956% |
| Accustem Sciences Inc. | 3.74 Million USD | 62.084% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 98.347% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -167.032% |
| Q BioMed Inc. | 3.43 Million USD | 58.666% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 94.252% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | 45.937% |
| Biomind Labs Inc. | 994.18 Thousand USD | -42.882% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 98.57% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | 19.274% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 78.855% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | 23.808% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 5782.036% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 91.127% |
| Curative Biotechnology, Inc. | 1.83 Million USD | 22.592% |
| Alpha Cognition Inc. | 9.7 Million USD | 85.364% |
| HST Global, Inc. | 140.9 Thousand USD | -908.118% |
| CSL Limited | 3.44 Billion USD | 99.959% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -26.278% |
| Halberd Corporation | 74.84 Thousand USD | -1798.01% |
| Enzolytics Inc. | 2.17 Million USD | 34.824% |
| Agentix Corp. | 1.37 Million USD | -3.554% |
| Resverlogix Corp. | 12.71 Million USD | 88.825% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | 61.089% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.907% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -36.064% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | 40.934% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | 10.058% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | 58.281% |
| AVAX Technologies, Inc. | 7.31 Million USD | 80.568% |
| Zenith Capital Corp. | 8.94 Million USD | 84.116% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.828% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -8054.004% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | 42.146% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -728.242% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | 26.05% |
| Kadimastem Ltd | 2.41 Million USD | 41.06% |
| Helix BioMedix, Inc. | 1.97 Million USD | 27.967% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 86.928% |
| BioStem Technologies, Inc. | 22.97 Million USD | 93.817% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -682.714% |
| LadRx Corporation | 3.81 Million USD | 62.734% |
| Cell Source, Inc. | 4.32 Million USD | 67.158% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -53.816% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -53.816% |
| NovAccess Global Inc. | 2.46 Million USD | 42.414% |
| Affymax, Inc. | 39.38 Million USD | 96.393% |
| Itoco Inc. | 919.14 Thousand USD | -54.547% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 66.485% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -26.945% |
| Mobile Lads Corp. | 554.54 Thousand USD | -156.157% |
| CytoDyn Inc. | 18.05 Million USD | 92.134% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -5543.883% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -545.457% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -0.051% |
| SYBLEU INC | 160.87 Thousand USD | -782.984% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | 21.792% |
| International Stem Cell Corporation | 5.27 Million USD | 73.05% |
| Bioxytran, Inc. | 3.82 Million USD | 62.815% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -2598.433% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -6882.79% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 96.083% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | 12.206% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -93.047% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | 54.339% |
| Neutra Corp. | 243.82 Thousand USD | -482.603% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 91.863% |
| PureTech Health plc | 144.59 Million USD | 99.018% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 93.067% |
| IXICO plc | 4.7 Million USD | 69.821% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 83.852% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 98.794% |
| CSL Limited | 3.89 Billion USD | 99.964% |
| Cellectis S.A. | 97.32 Million USD | 98.54% |